

Drug Monograph

Drug Name: **Asmanex® HFA (mometasone furoate) 50 mcg Inhalation**
 Drug Class: **Inhaled Corticosteroid**
 Prepared For: MO HealthNet
 Prepared By: Conduent

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Asmanex HFA is now available as 50 mcg strength in a 120 metered dose inhaler.

Manufacturer: Manufactured for: Merck and Co., Inc., Whitehouse Station, NJ 08889.

Indications: Asmanex is indicated for the maintenance treatment of asthma in patients 5 years of age and older. The 50 mcg dosage is indicated for children aged 5 to < 12 years of age

Costs: \$177 per 120 dose inhaler. Wholesale Acquisition Cost

Summary of Findings: This drug is being considered for inclusion in the state specific Preferred Drug List (PDL) as non-preferred.

Status Recommendation: Clinical Edit PA Required
 Open Access PDL

Type of PA Criteria: Appropriate Indications Non-Preferred
 No PA Required Preferred

Prepared by: Tyler Woods PharmD
 Date: March 15, 2020